Cohance Lifesciences Ltd reports Q2 FY27 revenue of ₹476.65 crore and net profit of ₹15.22 crore
- Revenue rose 12.9% sequentially but fell 14.2% year-on-year; adjusted EBITDA margin improved to 10% from 2.2% in Q1 FY27.
- Net profit compared with a ₹24.12 crore loss in Q1 FY27 and ₹74.08 crore profit in Q2 FY26; no exceptional item was reported, and limited-review conclusions were unmodified.
- Board approved Dr. Kuber Jagdale’s appointment as CTO and Executive Director, subject to shareholder approval, and a proposed 26% investment in a captive solar-generation SPV.
- Company disclosed a TGPCB closure order for its Suryapet facility following an industrial accident.
